IGC Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on October 10, 2025, specifically the results of IGC Pharma, Inc.'s 2025 Annual Meeting of Stockholders. The company is incorporated in Maryland and trades on the NYSE American under the symbol IGC.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Voting Results
Stockholders approved four key proposals at the Annual Meeting. The total shares voted were 53,776,307, representing approximately 59.22% of the 90,809,112 shares outstanding.
- Director Elections: Mr. Ram Mukunda and Mr. James Moran were elected as Class C directors to serve until the 2028 annual meeting.
- Accounting Firm Ratification: Manohar Chowdhry & Associates was ratified as the independent registered public accounting firm for the 2026 fiscal year.
- Equity Incentive Plan: Stockholders approved the grant of 5,000,000 shares of common stock to be issued to employees, advisors, directors, and consultants based on board-set metrics.
- Capital Structure Amendment: The authorized number of common shares was increased from 150,000,000 to 600,000,000 shares.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of specific risks or contingencies. Regarding executive compensation, the Board determined, based on a non-binding advisory vote, that stockholder votes on executive compensation will occur every three years.
Investor Verification Checklist
- Verify the impact of the 450,000,000 share increase in authorized capital on potential future dilution.
- Review the specific vesting and performance metrics for the newly approved 5,000,000 share equity grant.
- Confirm the tenure and background of the newly elected directors, Ram Mukunda and James Moran.
- Check subsequent filings for the company's 2025 financial results, as they are not included in this 8-K.